ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 227 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,782 | +27.3% | 74,400 | 0.0% | 0.06% | +1.6% |
| Q1 2023 | $1,400 | -99.9% | 74,400 | 0.0% | 0.06% | +3.4% |
| Q4 2022 | $1,184,448 | -2.7% | 74,400 | 0.0% | 0.06% | -14.5% |
| Q3 2022 | $1,217,000 | +16.1% | 74,400 | 0.0% | 0.07% | -9.2% |
| Q2 2022 | $1,048,000 | -41.8% | 74,400 | 0.0% | 0.08% | -2.6% |
| Q1 2022 | $1,802,000 | +3.8% | 74,400 | 0.0% | 0.08% | +23.8% |
| Q4 2021 | $1,736,000 | +40.5% | 74,400 | 0.0% | 0.06% | +57.5% |
| Q3 2021 | $1,236,000 | -31.9% | 74,400 | 0.0% | 0.04% | -11.1% |
| Q2 2021 | $1,815,000 | – | 74,400 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |